Evidence map›Paper›PMID 29388323›Full record

ArticleCNS neuroscience & therapeutics2018

Effects of repeated long-term psychosocial stress and acute cannabinoid exposure on mouse corticostriatal circuitries: Implications for neuropsychiatric disorders.

Jordi Tomas-Roig, Fabiana Piscitelli, Vanesa Gil, Ester Quintana, Lluís L Ramió-Torrentà, Jose Antonio Del Río, Timothy Patrick Moore, Hope Agbemenyah, Gabriela Salinas, Claudia Pommerenke and 5 more

Open access · hybridAbstract read
In one paragraph

Article in CNS neuroscience & therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 3 countries.

Jordi Tomas-RoigDepartment of Psychiatry and Psychotherapy, University of Göttingen, Göttingen, Germany.ORCID 0000-0002-8997-3436
Fabiana PiscitelliEndocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli, Italy.
Vanesa GilInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain.
Ester QuintanaGirona Neuroimmunology and Multiple Sclerosis Unit (UNIEMTG), Dr. Josep Trueta University Hospital and Neurodegeneration and Neuroinflammation Research Group, Girona Biomedical Research Institute (IDIBGI), Girona, Spain.
Lluís L Ramió-TorrentàGirona Neuroimmunology and Multiple Sclerosis Unit (UNIEMTG), Dr. Josep Trueta University Hospital and Neurodegeneration and Neuroinflammation Research Group, Girona Biomedical Research Institute (IDIBGI), Girona, Spain.
Jose Antonio Del RíoInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain.
Timothy Patrick MooreDepartment of Psychiatry and Psychotherapy, University of Göttingen, Göttingen, Germany.
Hope AgbemenyahLaboratory for Aging and Cognitive Diseases, European Neuroscience Institute, Goettingen, Germany.
Gabriela SalinasDepartment of Developmental Biochemistry, Georg-August-Universität Göttingen, Göttingen, Germany.
Claudia PommerenkeDepartment of Developmental Biochemistry, Georg-August-Universität Göttingen, Göttingen, Germany.
Stephan LorenzenDepartment of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany.
Tim BeißbarthDepartment of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany.
Sigrid Hoyer-FenderJohann-Friedrich-Blumenbach Institute for Zoology and Anthropology, Developmental Biology, Göttingen, Germany.
Vincenzo Di MarzoEndocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli, Italy.
Ursula Havemann-ReineckeDepartment of Psychiatry and Psychotherapy, University of Göttingen, Göttingen, Germany.
Institut d'Investigació Biomèdica de Girona · ESBiomedical Research Networking Center on Neurodegenerative Diseases · ESInstitute of Applied Science and Intelligent Systems · ITUniversitätsmedizin Göttingen · DEUniversity of Göttingen · DEEuropean Neuroscience Institute Göttingen · DENanoscale Microscopy and Molecular Physiology of the Brain Cluster of Excellence 171 — DFG Research Center 103 · DEUniversity Hospital Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionVulnerability to psychiatric manifestations is achieved by the influence of genetic and environment including stress and cannabis consumption. Here, we used a psychosocial stress model based on resident-intruder confrontations to study the brain corticostriatal-function, since deregulation of corticostriatal circuitries has been reported in many psychiatric disorders. CB AIMS AND

methodsThe investigation presented here is addressed to assess the impact of repeated stress following acute cannabinoid exposure on behavior and corticostriatal brain physiology by assessing mice behavior, the concentration of endocannabinoid and endocannabinoid-like molecules and changes in the transcriptome.

resultsStressed animals urinated frequently; showed exacerbated scratching activity, lower striatal N-arachidonylethanolamine (AEA) levels and higher cortical expression of cholinergic receptor nicotinic alpha 6. The cannabinoid agonist WIN55212.2 diminished locomotor activity while the inverse agonist increased the distance travelled in the center of the open field. Upon CB

conclusionsThe endocannabinoid system had a direct effect on serotoninergic neurotransmission and glucocorticoid signaling. Cholinergic receptor nicotinic alpha-6 was shown to be deregulated in response to stress and following synthetic cannabinoid drugs thus could confer vulnerability to cannabis addiction and psychosis. Targeting the receptors of endocannabinoids and endocannabinoid-like mediators might be a valuable option for treating stress-related neuropsychiatric symptoms.

Indexed as

AnimalsBody WeightCannabinoid Receptor AntagonistsCannabinoidsCerebral CortexCorpus StriatumDisease Models, AnimalExploratory BehaviorGene Expression RegulationMaleMiceMice, Inbred C57BLNeural PathwaysRimonabantRNA, MessengerStress, PsychologicalCannabinoid Receptor AntagonistsCannabinoidsRimonabantRNA, MessengerTacrolimus Binding Protein 5Tacrolimus Binding ProteinsTirapazamineCB 1Chrna6 and Slc6a4Fkbp5psychosocial stress

Identifiers

PMID29388323
PMCPMC5969305
OpenAlexW2793368055

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.